156 related articles for article (PubMed ID: 33790117)
1. [Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
Wiriyasermkul P; Moriyama S; Kongpracha P; Nagamori S
Yakugaku Zasshi; 2021; 141(4):501-510. PubMed ID: 33790117
[TBL] [Abstract][Full Text] [Related]
2. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Kanai Y
Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
[TBL] [Abstract][Full Text] [Related]
3. The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.
Lu X
Curr Cancer Drug Targets; 2019; 19(11):863-876. PubMed ID: 31376820
[TBL] [Abstract][Full Text] [Related]
4. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
5. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.
Häfliger P; Charles RP
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100853
[TBL] [Abstract][Full Text] [Related]
6. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
[TBL] [Abstract][Full Text] [Related]
7. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.
Jin SE; Jin HE; Hong SS
Expert Opin Ther Targets; 2015; 19(10):1319-37. PubMed ID: 25968633
[TBL] [Abstract][Full Text] [Related]
8. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1).
Kongpracha P; Nagamori S; Wiriyasermkul P; Tanaka Y; Kaneda K; Okuda S; Ohgaki R; Kanai Y
J Pharmacol Sci; 2017 Feb; 133(2):96-102. PubMed ID: 28242177
[TBL] [Abstract][Full Text] [Related]
10. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
11. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Wang Z; Chi D; Wu X; Wang Y; Lin X; Xu Z; Liu H; Sun J; He Z; Wang Y
J Control Release; 2019 Dec; 316():22-33. PubMed ID: 31676386
[TBL] [Abstract][Full Text] [Related]
13. LAT1 is a central transporter of essential amino acids in human umbilical vein endothelial cells.
Hayashi K; Jutabha P; Kamai T; Endou H; Anzai N
J Pharmacol Sci; 2014; 124(4):511-3. PubMed ID: 24671056
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Ohshima Y; Kaira K; Yamaguchi A; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yokobori T; Miyazaki T; Asao T; Tsushima Y; Kuwano H; Ishioka NS
Cancer Sci; 2016 Oct; 107(10):1499-1505. PubMed ID: 27465934
[TBL] [Abstract][Full Text] [Related]
15. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
[TBL] [Abstract][Full Text] [Related]
16. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
[TBL] [Abstract][Full Text] [Related]
17. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.
Sato M; Harada-Shoji N; Toyohara T; Soga T; Itoh M; Miyashita M; Tada H; Amari M; Anzai N; Furumoto S; Abe T; Suzuki T; Ishida T; Sasano H
Sci Rep; 2021 Jan; 11(1):589. PubMed ID: 33436954
[No Abstract] [Full Text] [Related]
18. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
19. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.
Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Oriuchi N; Nagamori S; Kanai Y
Cancer Sci; 2016 Mar; 107(3):347-52. PubMed ID: 26749017
[TBL] [Abstract][Full Text] [Related]
20. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
